|
Press Releases |
|
|
|
Tuesday, December 1, 2020 |
|
BioVaxys Provides Viral Vaccine Platform Program Update |
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
Monday, November 30, 2020 |
|
BioVaxys Provides Viral Vaccine Platform Program Update |
BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
Wednesday, November 11, 2020 |
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
Monday, November 2, 2020 |
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 17, 2024 11:19 JST
|
|
|
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market
May 17, 2024 09:00: JST
|
|
|
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market
May 17, 2024 08:00 HKT/SGT
|
|
|
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
May 16, 2024 22:00 HKT/SGT
|
|
|
加速大灣區互聯互通,內地乘客可在曹操出行下單大巴直達港澳
May 16, 2024 21:52 HKT/SGT
|
|
|
DEXIS Innovation Continues With New DEXIS Ti2 Sensor as Successor to the DEXIS Titanium Sensor, the #1 Selling Intraoral Sensor in the United States
May 16, 2024 21:30 HKT/SGT
|
|
|
Horus: Million Dollar Air-Mail NFT Drop on Base
May 16, 2024 20:11 HKT/SGT
|
|
|
香港贸发局第三届「国际医疗健康周」正式展开
May 16, 2024 18:24 HKT/SGT
|
|
|
香港貿發局第三屆「國際醫療健康周」正式展開
May 16, 2024 18:15 HKT/SGT
|
|
|
HKTDC kicks off third International Healthcare Week
May 16, 2024 18:00 HKT/SGT
|
|
|
CleverTap's 2024 Market Research Report Unveils that Brands Implementing Higher AI Adoption See 4x Boost in Conversions
May 16, 2024 17:00 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 16, 2024 17:00 HKT/SGT
|
|
|
Q2 Metals Announces Re-Assay Results and Spring 2024 Exploration Plan for Cisco Lithium Property, James Bay Territory, Quebec, Canada
May 16, 2024 15:09 HKT/SGT
|
|
|
World CX Summit 2024: Steering the future of customer experience forward
May 16, 2024 15:05 HKT/SGT
|
|
|
Rover Announces and Closes $0.03 Unit Financing
May 16, 2024 05:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|